Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial.
Christodoulou M, Blackhall F, Mistry H, Leylek A, Knegjens J, Remouchamps V, Martel-Lafay I, Farré N, Zwitter M, Lerouge D, Pourel N, Janicot H, Scherpereel A, Tissing-Tan C, Peignaux K, Geets X, Konopa K, Faivre-Finn C. Christodoulou M, et al. Among authors: konopa k. J Thorac Oncol. 2019 Jan;14(1):63-71. doi: 10.1016/j.jtho.2018.09.027. Epub 2018 Oct 31. J Thorac Oncol. 2019. PMID: 30391573 Free PMC article. Clinical Trial.
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
Pérol M, Pavlakis N, Levchenko E, Platania M, Oliveira J, Novello S, Chiari R, Moran T, Mitry E, Nüesch E, Liu T, Balas B, Konopa K, Peters S. Pérol M, et al. Among authors: konopa k. Lung Cancer. 2019 Dec;138:79-87. doi: 10.1016/j.lungcan.2019.10.002. Epub 2019 Oct 11. Lung Cancer. 2019. PMID: 31654838 Clinical Trial.
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
Mok T, Peters S, Camidge DR, Noé J, Gadgeel S, Ou SI, Kim DW, Konopa K, Pozzi E, Liu T, Loftin IR, Williams C, Shaw AT. Mok T, et al. Among authors: konopa k. J Thorac Oncol. 2021 Feb;16(2):259-268. doi: 10.1016/j.jtho.2020.10.007. Epub 2020 Oct 24. J Thorac Oncol. 2021. PMID: 33334571 Free article. Clinical Trial.
Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance.
Jassem E, Bigda J, Dziadziuszko R, Schlichtholz B, Le Roux D, Grodzki T, Rzyman W, Konopa K, Poberezna M, Dobrzańska Z, Skokowski J, Soussi T, Jassem J. Jassem E, et al. Among authors: konopa k. Lung Cancer. 2001 Jan;31(1):17-23. doi: 10.1016/s0169-5002(00)00150-1. Lung Cancer. 2001. PMID: 11162862
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).
Karlovich C, Goldman JW, Sun JM, Mann E, Sequist LV, Konopa K, Wen W, Angenendt P, Horn L, Spigel D, Soria JC, Solomon B, Camidge DR, Gadgeel S, Paweletz C, Wu L, Chien S, O'Donnell P, Matheny S, Despain D, Rolfe L, Raponi M, Allen AR, Park K, Wakelee H. Karlovich C, et al. Among authors: konopa k. Clin Cancer Res. 2016 May 15;22(10):2386-95. doi: 10.1158/1078-0432.CCR-15-1260. Epub 2016 Jan 8. Clin Cancer Res. 2016. PMID: 26747242 Free PMC article. Clinical Trial.
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
Dziadziuszko R, Peters S, Mok T, Camidge DR, Gadgeel SM, Ou SI, Konopa K, Noé J, Nowicka M, Bordogna W, Morcos PN, Smoljanovic V, Shaw AT. Dziadziuszko R, et al. Among authors: konopa k. Clin Cancer Res. 2022 May 2;28(9):1800-1808. doi: 10.1158/1078-0432.CCR-21-2840. Clin Cancer Res. 2022. PMID: 35275991 Free PMC article. Clinical Trial.
25 results